Inclusion Criteria:

Eligibility will be determined separately for Part I and Part II of this study:

Part I ( Part I Eligibility criteria (eligibility for undergoing apheresis procedure)

- Age ≤ 25 years at initial diagnosis.

- Must have one of the following diagnoses:

- High risk neuroblastoma

- Metastatic or recurrent retinoblastoma

- High risk rain tumors

- Recurrent or refractory Hodgkin disease

- Recurrent or advanced stage Wilms tumor

- Recurrent or metastatic sarcomas

- Recurrent or refractory non-Hodgkin lymphoma

- Desmoplastic small round cell tumor.

- Lansky or Karnofsky Performance Score ≥ 70.

- Creatinine ≤ 2.0 mg/dl.

- Direct bilirubin ≤ 2.0 mg/dl.

- SGPT ≤ 2 x upper limit of normal

- HIV testing

- Negative pregnancy test

- Patients with significant prior radiation therapy to the liver will be excluded.

Part II eligibility criteria (criteria for transplantation of CD133 select stem cell
product)

- Successfully completed Part I of protocol treatment plan and has the following
available:

- Stored autologous bone marrow or peripheral blood stem cells (i.e. 2 x 106 unselected
CD34+ cells/ kg PBSC or 1 x 106 CD34+ cells/ kg BM) for back up.

- Stored autologous bone marrow or peripheral blood stem cells (2 x 106 CD133+ cells/
kg PBSC or 2 x 106 CD133+ cells/ kg BM) for infusion.

- Forced vital capacity greater than or equal to 40% normal or pulse oximetry greater
than or equal to 92% on room air.

- Lansky or Karnofsky Performance Score ≥ 70.

- Creatinine ≤ 2.0 mg/dl.

- Direct bilirubin ≤ 2.0 mg/dl.

- SGPT ≤ 2 x upper limit of normal

- Negative pregnancy test

- Patients with significant prior radiation therapy (in opinion of the PI) to the liver
will be excluded.